ArticleOncology letters2026
Combination of vinorelbine capsules and the small molecule anti-angiogenic drug apatinib for first-line treatment of advanced triple-negative breast cancer with schizophrenia after failure of anthracycline and taxane therapy: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with metastatic triple-negative breast cancer (mTNBC) face a poor prognosis, with limited treatment options and short progression-free survival. Chemotherapy remains a cornerstone in the treatment of mTNBC, but median overall survival is limited to 2-3 years. Oral vinorelbine, whether used alone or in combination with other agents, has demonstrated efficacy in treating metastatic breast cancer. Anti-angiogenic drugs also hold promise for managing advanced breast cancer. The present study reports a case of a patient with advanced TNBC and schizophrenia who progressed following adjuvant chemotherapy with anthracyclines and taxanes. Following recurrence and metastasis, the patient was treated with first-line vinorelbine capsules combined with the small molecule anti-angiogenic drug apatinib, and achieved partial remission. The initial time to first progression (due to patient-led treatment discontinuation) was 14 months; however, despite multiple interruptions and rechallenges, the combination provided long-term disease control spanning over 6 years from the start of first-line therapy. Due to the high cost of apatinib, the patient discontinued it and switched to a regimen of vinorelbine capsules combined with capecitabine. The present case demonstrated that while the combination showed efficacy, treatment adherence and cost were major limitations. These findings indicated that vinorelbine capsules combined with apatinib offered notable efficacy and acceptable safety in this patient with schizophrenia, thus representing a potential therapeutic option for advanced TNBC, but further study is warranted. Notably, the combined treatment did not induce or worsen the patient's schizophrenia. Overall, the present case provided valuable insights in treating patients with breast cancer with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.